Understanding CKD among patients with T2DM: prevalence, temporal trends, and treatment patterns—NHANES 2007–2012

Bingcao Wu; Kelly Bell; Amy Stanford; David M Kern; Ozgur Tunceli; Suma Vupputuri; Iftekhar Kalsekar; Vincent Willey

doi:10.1136/bmjdrc-2015-000154

Back

Understanding CKD among patients with T2DM: prevalence, temporal trends, and treatment patterns—NHANES 2007–2012

Journal article

Open access

Peer reviewed

Understanding CKD among patients with T2DM: prevalence, temporal trends, and treatment patterns—NHANES 2007–2012

Bingcao Wu, Kelly Bell, Amy Stanford, David M Kern, Ozgur Tunceli, Suma Vupputuri, Iftekhar Kalsekar and Vincent Willey

BMJ open diabetes research & care, Vol.4(1), pp.e000154-e000154

04/2016

DOI: 10.1136/bmjdrc-2015-000154

PMCID: PMC4838667

PMID: 27110365

Files and links (1)

url

https://doi.org/10.1136/bmjdrc-2015-000154View

Published (Version of record) Open Access

Abstract

ObjectiveTo describe the estimated prevalence and temporal trends of chronic kidney disease (CKD) treatment patterns, and the association between CKD and potential factors for type 2 diabetes mellitus (T2DM) in different demographic subgroups.Research design and methodsThis was a cross-sectional analysis of adults with T2DM based on multiple US National Health and Nutrition Examination Survey (NHANES) datasets developed during 2007–2012. CKD severity was defined according to the Kidney Disease: Improving Global Outcomes (KDIGO) 2012 guidelines using the CKD Epidemiology Collaboration (CKD-EPI) equation: mild to moderate=stages 1–3a; moderate to kidney failure=stages 3b–5. Multivariable logistic regression analyses were performed to assess the associations between CKD and potential factors.ResultsOf the adult individuals with T2DM (n=2006), age-adjusted CKD prevalence was 38.3% during 2007–2012; 77.5% were mild-to-moderate CKD. The overall age-adjusted prevalence of CKD was 40.2% in 2007–2008, 36.9% in 2009–2010, and 37.6% in 2011–2012. The prevalence of CKD in T2DM was 58.7% in patients aged ≥65 years, 25.7% in patients aged <65 years, 43.5% in African-Americans and Mexican-Americans, and 38.7% in non-Hispanic whites. The use of antidiabetes and antihypertensive medications generally followed treatment guideline recommendations. Older age, higher hemoglobin A1c (HbA1c), systolic blood pressure (SBP), and having hypertension were significantly associated with CKD presence but not increasing severity of CKD.ConclusionsCKD continued to be prevalent in the T2DM population; prevalence remained fairly consistent over time, suggesting that current efforts to prevent CKD could be improved overall, especially by monitoring certain populations more closely.

Details

Title: Subtitle: Understanding CKD among patients with T2DM: prevalence, temporal trends, and treatment patterns—NHANES 2007–2012
Creators: Bingcao Wu - HealthCore Inc. , Wilmington, Delaware , USA.
Kelly Bell - AstraZeneca R&D , Fort Washington, Pennsylvania , USA.
Amy Stanford - Bristol-Myers Squibb (Germany)
David M Kern - HealthCore Inc. , Wilmington, Delaware , USA.
Ozgur Tunceli - HealthCore Inc. , Wilmington, Delaware , USA.
Suma Vupputuri - HealthCore Inc. , Wilmington, Delaware , USA.
Iftekhar Kalsekar - AstraZeneca R&D , Fort Washington, Pennsylvania , USA.
Vincent Willey - HealthCore Inc. , Wilmington, Delaware , USA.
Resource Type: Journal article
Publication Details: BMJ open diabetes research & care, Vol.4(1), pp.e000154-e000154
DOI: 10.1136/bmjdrc-2015-000154
PMID: 27110365
PMCID: PMC4838667
NLM abbreviation: BMJ Open Diabetes Res Care
ISSN: 2052-4897
eISSN: 2052-4897
Grant note: DOI: 10.13039/100004325, name: AstraZeneca
Language: English
Date published: 04/2016
Academic Unit: Stead Family Department of Pediatrics; Neonatology
Record Identifier: 9984353831702771

Metrics

13 Record Views

166 Times Cited - Web of Science